Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 20 (oversold) · MACD above its signal · 1% above its 52-week low
None of the 29 investors followed here reported a position in CLLS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CLLS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CLLS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -21.7 | 2.4 | -18.3 | 23.0 | -9.7 | -14.8 | -8.3 | 21.8 | -54.9 | -27.2 | −77.3% | ||
| 2025 | -10.6 | -19.9 | -3.9 | 32.7 | -11.2 | 4.5 | 64.6 | 2.5 | 10.8 | 21.1 | 47.0 | -4.5 | +168.9% |
| 2024 | -2.9 | -13.7 | 2.7 | -3.4 | 5.9 | -31.0 | 19.8 | 7.1 | -11.7 | -16.0 | 18.0 | -14.3 | −41.6% |
| 2023 | 45.2 | -27.5 | -12.7 | -2.6 | 1.1 | 3.6 | 8.7 | -3.3 | -23.7 | -38.6 | 207.2 | 3.4 | +46.7% |
| 2022 | -23.5 | -27.1 | 0.2 | -22.9 | 3.4 | -21.8 | -7.4 | 26.3 | -30.8 | 8.5 | -11.5 | -4.5 | −74.1% |
| 2021 | 1.0 | -21.4 | -6.0 | -7.9 | -15.8 | -1.3 | -16.3 | 11.0 | -12.3 | -14.7 | -19.9 | -5.8 | −70.0% |
| 2020 | -9.6 | 1.0 | -41.1 | 41.8 | 41.5 | -3.6 | -11.8 | 17.5 | 0.3 | -14.0 | 59.5 | 6.7 | +58.1% |
| 2019 | 6.1 | 1.2 | 2.6 | 7.6 | -19.6 | -1.8 | -6.7 | -16.3 | -14.6 | 14.0 | 17.2 | 23.2 | +2.8% |
| 2018 | 7.9 | -0.8 | 0.9 | -8.9 | 4.3 | -5.5 | 2.2 | 2.0 | -4.2 | -10.0 | -13.3 | -24.4 | −42.9% |
| 2017 | 7.6 | 22.3 | 7.6 | 0.5 | -1.2 | 8.4 | -6.2 | 18.8 | -1.1 | 23.1 | -28.8 | 16.9 | +72.0% |
| 2016 | -27.9 | 6.5 | 15.5 | -1.1 | 20.5 | -18.9 | -0.8 | 0.6 | -9.2 | -26.6 | -4.6 | 0.5 | −45.4% |
| 2015 | -4.9 | 30.4 | -15.9 | -0.9 | -4.3 | -23.0 | 0.3 | 25.1 | -6.2 | −10.3% |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Buy / hold / sell counts